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*Shown are the numbers of patients and the percentage of patients with a given type of Grade 3 or 4 adverse events, and the total number of events in each category. Recurrent laboratory events in the same patient were counted as a single event. P values were calculated for chi-square or Fisher's exact tests for the proportion of patients affected. † Shown are absolute differences in the proportions of patients affected in each group ‡ Renal events were nephrolithiasis, pyelonephritis in OT group and renal cell carcinoma, end-stage renal failure (progression of existing chronic renal impairment present at study entry) and acute renal impairment (transient, accompanying episode of pneumonia) in PI-mono group. § CNS events were depression and/or suicidal ideation (4), anxiety/stress (2), headache (2), psychosis (1), and normal pressure hydrocephalus (1) in the OT group; depression and/or suicidal ideation (9), anxiety/stress (1), headache (2), myasthenia gravis (1), psychosis (2); psychiatric symptoms, unspecified (1), meningioma (1), glioblastoma (1), head injury (1) and convulsion (1) in the PI-mono group 7 Supplementary 
SUPPLEMENTARY FIGURE 2: Time to virological rebound -extended definition
Extended definition of VL rebound included protocol-defined confirmed VL rebound cases as well as those that were changed earlier (i.e. at less than 4 weeks after the first detectable VL or after only 2 detectable VLs). Number (proportion) of rebound by end of follow-up: 9 (4.0%) in OT, and 105 (42.0%) in PI-mono (risk difference 38.0% [95%-CI: 29.2-46.8%]; P < 0.001). In PI-mono, rate of rebound is 27 per 100 person years in the first year, and 6 per 100 person years in subsequent years.
